ŌURA Health, Dyno Therapeutics, Heartbeat Health
Oculis Closes US$57M Series C Financing
Oculis S.A., a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing.
The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors.
Led by Riad Sherif, MD, CEO, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients.
Proceeds from this financing will advance the company’s late-stage topical Ophthalmic portfolio, including: – Moving OCS-01 into Phase 3 trials in Diabetic Macular Edema (DME) and complete registration studies in the treatment of Inflammation and Pain following Ocular Surgery.
Oculis Closes US$57M Series C Financing - FinSMEs
Oculis S.A., a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing
Laevoroc Oncology Raises Over USD 1.1M in Seed Funding
Laevoroc Oncology (formerly known as TNT-Medical Corporation), a Zug, Switzerland-based oncology development group of companies, raised over USD 1.1m in seed funding.
The company intends to use the funds to expand operations and its business reach.
Founded in 2019 by Thomas Mehrling MD PhD, and Davide Guggi PhD, Laevoroc Oncology is an oncology development group of companies, pursuing an asset-centric business model with three subsidiaries (chemotherapy, immunology and neuro-oncology) covering a pipeline that spans breakthrough innovation through to re-imagining approved therapies.
Laevoroc Oncology Raises Over USD 1.1M in Seed Funding - FinSMEs
Laevoroc Oncology (formerly known as TNT-Medical Corporation), a Zug, Switzerland-based oncology development group of companies, raised over USD 1.1m in seed funding
Oura Raises $100M in Series C Funding
ŌURA Health, an Oulu, Finland-based provider of a health tech wearable that provides daily personalized sleep and overall health insights, raised $100m in Series C funding.
The round, which brought total funding to $148.3m, was led by The Chernin Group and Elysian Park, the investment arm of the LA Dodgers; Temasek, JAZZ Venture Partners, and Eisai Co., Ltd.; growth investors Bedford Ridge and One Capital, as well as existing investors Forerunner Ventures, Square, MSD Capital, Marc Benioff, Lifeline Ventures, Metaplanet Holdings, and Next Ventures.
The company intends to use the funds to invest in all areas of business, including Software and Hardware Development, People, Research & Development, Marketing, and Customer Experience.
Led by Harpreet Singh Rai, CEO, Oura provides a health tech wearable that provides actionable insights on sleep and its impact on overall health. The ring tracks all stages of sleep and accounts for daily activity to provide practical steps for long-term improvement.
Oura Raises $100M in Series C Funding - FinSMEs
ŌURA Health, an Oulu, Finland-based provider of a health tech wearable that provides daily personalized sleep and overall health insights, raised $100m in Series C funding
Eventum Orthopaedics Raises £1.4M in Funding
Eventum Orthopaedics, an Ilkley, Yorkshire, UK-based medtech startup, secured £1.4m in funding.
The round was led by NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, Mercia’s EIS funds and private investors including several orthopaedic surgeons.
The company intends to use the funds to finalize development and bring the product to market in 2022.
Founded by John Naybour and Paul Atherton, who have been joined by Mike Cripps, the former MD of Leeds-based Panintelligence, as Non-Executive Director and Jon Gonzales as Finance Director, Eventum has developed a device that will provide real-time measurements of the area during knee replacement operations, enabling surgeons to improve their decision making.
Eventum Orthopaedics Raises £1.4M in Funding
Eventum Orthopaedics, an Ilkley, Yorkshire, UK-based medtech startup, secured £1.4m in funding
Dyno Therapeutics Closes $100M Series A Financing
Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing.
The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen Horowitz, joined the company’s board of directors.
Led by Eric Kelsic, PhD, founder and CEO, Dyno Therapeutics is advancing the CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors, broadening the functionality and enhancing the therapeutic impact of gene therapies developed by its biopharmaceutical partners.
The company intends to use the capital to expand its CapsidMap™ platform. Proceeds from the financing will accelerate building Dyno’s CapsidMap platform to design improved vectors targeting liver, muscle, eye and central nervous system (CNS) disease, as well as growing into new areas of lung, heart and kidney disease.
Dyno Therapeutics Closes $100M Series A Financing - FinSMEs
Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing
Esker Therapeutics Launches $70M Series A Financing
Esker Therapeutics, a San Francisco, CA-based precision medicine company, raised $70m in Series A financing.
Foresite Capital made the investment.
The company intends to use the funds to advance its pipeline, including a highly selective, clinical-stage TYK2 inhibitor and early-stage discovery programs.
Its pipeline is led by ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1 compared to current therapies in development. It is initially being developed for the treatment of psoriasis and is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.
Led by June Lee, M.D., founder, president and chief executive officer, Esker Therapeutics is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Esker Therapeutics Launches $70M Series A Financing - FinSMEs
Esker Therapeutics, a San Francisco, CA-based precision medicine company, raised $70m in Series A financing
Sporos Bioventures Raises $38.1M in Series A Financing
Sporos Bioventures, LLC, a Houston, TX-based company formed to catalyze the development of therapies that target novel disease mechanisms in cancer and immune diseases, closed a $38.1m Series A financing.
The company plans to use the proceeds to support the development of lead assets across its portfolio and build out the team.
Sporos identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines. Its current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.
Its most advanced company, Tvardi, is developing small molecule inhibitors to STAT3, a key regulatory protein integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that Tvardi’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity across a broad range of tumors including multiple durable responses.
Sporos Bioventures Raises $38.1M in Series A Financing - FinSMEs
Sporos Bioventures, LLC, a Houston, TX-based company formed to catalyze the development of therapies that target novel disease mechanisms in cancer and immune diseases, closed a $38.1m Series A financing
Aerobiotix Raises $25M in Growth Equity Financing
Aerobiotix, a Miamisburg, Ohio-based global medical company, raised $25m in equity financing.
The round was led by Vivo Capital with participation from Asahi Kasei Ventures.
The company intends to use the funds to accelerate sales, marketing, and new product development.
Founded in 2013 by Dr. David Kirschman, CEO, Aerobiotix makes airborne infection control products that provide real-time, in room solutions for hospitals, ASCs, long term care and office based settings.
The company’s infection control products have been used to support thousands of procedures across multiple surgical specialty disciplines and in over 175 hospitals and multiple long-term care facilities.
Aerobiotix Raises $25M in Growth Equity Financing - FinSMEs
Aerobiotix, a Miamisburg, Ohio-based global medical company, raised $25m in equity financing
Heartbeat Health Raises $20M in Series B Funding
Heartbeat Health, a NYC-based healthcare company working to deliver heart care, raised $20m in Series B funding.
The round was led by Echo Health Ventures, with participation from DaVita Venture Group and existing investors, .406 Ventures, Optum Ventures, Kindred Ventures, Lerer Hippeau, Designer Fund and Max Ventures. Jessica Zeaske, a Partner at Echo Health Ventures, will join the Board of Directors at Heartbeat.
The company intends to use the funds to accelerate product research and development as well as expand clinical services offered to at-risk organizations.
Led by Dr. Jeff Wessler, CEO, Nayan Jain, CTO, and Mark Hanson, Chief Product Officer, Heartbeat Health is a healthcare technology company that delivers virtual-first cardiovascular disease prevention and management with a focus on improved clinical experience, health outcomes, and reduced cost. The Heartbeat virtual-first platform offers a data-powered patient and provider experience, combining telemedicine, diagnostic coordination, medication management, lifestyle guidance, and stakeholder engagement.
Heartbeat Health Raises $20M in Series B Funding - FinSMEs
Heartbeat Health, a NYC-based healthcare company working to deliver heart care, raised $20m in Series B funding
Therini Bio Raises $17M in Seed Funding
Therini Bio, Inc., a South San Francisco, CA-based vascular biology company, raised 17m in seed extension round of financing.
The round was co-led by SV Health Investors’ Impact Medicine Fund, MRL Ventures, and Sanofi Ventures who join existing investors including the Dementia Discovery Fund and Dolby Family Ventures, as well as new investor, Foundation for a Better World. With the closing of the financing Dr. Christine Brennan, PhD from MRL Ventures and Dr. Jim Trenkle, PhD from Sanofi Ventures have joined the Therini board of directors.
The company intends to use the capital to accelerate the development of its lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Co-founded by Dr. Katerina Akassoglou, PhD, and Dan Burgess, President and CEO, Therini Bio is a vascular biology company focused on discovering and developing therapeutics targeting fibrin, a new biological target for neurological and peripheral diseases. In 2020, the company announced initial seed funding of $9.35m led by the Dementia Discovery Fund, Dolby Family Ventures and Alzheimer’s Drug Discovery Foundation.
Therini Bio Raises $17M in Seed Funding - FinSMEs
Therini Bio, Inc., a South San Francisco, CA-based vascular biology company, raised 17m in seed extension round of financing
Outcomes4Me Raises $12M in Series A Funding Round
Outcomes4Me Inc., a Cambridge, Mass.-based developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, raised $12m in Series A funding round.
The round was led by Northpond Ventures, with participation from all existing investors, including Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures Director, will join Outcomes4Me’s board.
The company intends to use the funds to extend its platform beyond breast cancer to other cancers, grow the platform’s regulatory-grade dataset, and expand to more patients in Europe.
Co-founded in 2017 by Maya R. Said, Sc. D., CEO, and Dr. Osama Rahma, Chief Medical Advisor, who were later joined by Chief Operating Officer Sami Shalabi, a former Google executive who sold his company to Google and co-founded and led Google Play Newsstand and the all-new Google News, growing both to over a billion users, Outcomes4Me has developed an Artificial Intelligence (AI)-powered patient empowerment platform for shared decision-making between patients and providers. The solution harnesses regulatory-grade, real-world data and patient experiences to generate deeper insights that improve care, accelerate research and achieve better outcomes.
Outcomes4Me Raises $12M in Series A Funding Round - FinSMEs
Outcomes4Me Inc., a Cambridge, Mass.-based developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, raised $12m in Series A funding round
Alebund Pharmaceuticals Raises $60M in Series B Financing
Alebund Pharmaceuticals, a Shangai, China-based biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, raised $60m in Series B financing.
The round was led by Quan Capital, with participation from 3E Bioventures Capital, and Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Med-Fine Capital.
The company intends to use the funds for research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion its talent pool.
Founded in Shanghai in early 2018 as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures, Alebund is a clinical stage biopharmaceutical company dedicated to the discovery and development of novel therapies and providing clinical solutions to patients with kidney diseases and related chronic conditions.